Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination?

Clin Ther. 2017 Mar;39(3):659-660. doi: 10.1016/j.clinthera.2017.01.029. Epub 2017 Feb 9.

Abstract

Cardiovascular disease is the leading cause of death in the world. Dyslipidemia, manifested by elevated low-density lipoprotein cholesterol (LDL-C) levels, is central to the development and progression of atherosclerosis. Dyslipidemia has become a primary target of intervention in strategies for the prevention of cardiovascular events. Therapeutic lifestyle changes, such as increased physical activity, weight loss, smoking cessation, and adoption of a healthier diet, are effectively reducing cardiovascular risk in primary and secondary prevention. The combination therapy lowered LDL-C levels and achieved the LDL-C target in patients with high cardiovascular risk.

Keywords: cardiovascular risk; dyslipidemia; lipids; statins.

MeSH terms

  • Atherosclerosis / drug therapy*
  • Cardiovascular Diseases / prevention & control*
  • Cholesterol, LDL / blood
  • Dyslipidemias / drug therapy*
  • Humans
  • Life Style
  • Risk Factors
  • Secondary Prevention

Substances

  • Cholesterol, LDL